André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.

Slides:



Advertisements
Similar presentations
MAIN-COMPARE Study Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
Advertisements

Steroids In caRdiac Surgery (SIRS) Trial
Is this the “spioenkop” for CABG?
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
ARTS I & II Keith D Dawkins Southampton University Hospital.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
5 Years Results of Off-Pump VS On-Pump CABG 5 Years Results of Off-Pump VS On-Pump CABG Prospective Non-randomized Comparative Study Piya Cherntanomwong*,
Population Health Research Institute Hamilton Health Sciences/McMaster University Hamilton, Canada Steroids In caRdiac Surgery (SIRS) Trial SIRS was funded.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
Clinical Outcomes with Newer Antihyperglycemic Agents
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
An International Randomized Trial of Early Versus Delayed Invasive Strategies in Patients with Non-ST Segment Elevation Acute Coronary Syndromes TIMACS.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
Global Variations in the 1-year Rates of Death and Stroke in Patients Presenting to the Emergency Department with Atrial Fibrillation Results from the.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
1 HOT LINE PRESENTATION World Congress of Cardiology 2006 Barcelona, Spain September 5, 2006 Warfarin Antiplatelet Vascular Evaluation PAD Patients.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The Heart Outcomes Prevention Evaluation (HOPE) – 3 Trial
Angela Aziz Donnelly April 5, 2016
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
David J McCormack MFSTEd FRCSEd (CTh) Advanced Clinical Fellow
The German Off-Pump Coronary Artery Bypass Grafting in
Single IMA {Single Arterial}
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Andre Lamy on behalf of the COMPASS Investigators
Balloon-pump assisted Coronary Intervention Study (BCIS-1):
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Jeff Macemon Waikato Cardiothoracic Unit
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
Dabigatran in myocardial injury after noncardiac surgery
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
The Hypertension in the Very Elderly Trial (HYVET)
Dr. PJ Devereaux on behalf of POISE Investigators
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
for the REGROUP Trial Investigators
Dr. PJ Devereaux on behalf of POISE Investigators
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Presenter Disclosure Information
Presentation transcript:

André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures : CORONARY was funded by a grant from the Canadian Institutes of Health Research (CIHR). CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year

Benefits and risks of performing CABG surgery on beating heart (off pump) not clearly established. Meta-analyses of 59 trials involving 8961 pts – No differences in major CV outcomes except strokes ROOBY (1 Year) – Primary Outcome: Off-pump is worse (p=0.04) – CV Deaths: Off-pump is worse (p=0.03) Background 2

79 centers in 19 countries 4,752 patients recruited between (November 2006 October 2011) Designed, coordinated, managed and data analysed and reported by the Population Health Research Institute, Hamilton Health Sciences and McMaster University in Hamilton, Canada The data was monitored by independent DSMB Funded by Canadian Institutes of Health Research CORONARY Trial Organization 3

-Off pump CABG compared to on-pump CABG would reduce major clinical events in short-term (30 Days) -Benefits maintained in long-term (5 yrs) Study Hypotheses 4

Inclusion Criteria – Isolated CABG with median sternotomy – One of the following: 1.Peripheral vascular disease 2.Cerebrovascular disease 3.Renal Insufficiency 4.Age ≥ 70 years 5.Age with at least one risk factor (diabetes, urgent revascularization, smoker, LVEF ≤ 35%) 6.Age with at least two of the above risk factors Exclusions – Additional cardiac procedure planned – Contraindications to off-pump or on-pump CABG – Emergency or re-do CABG Inclusion/Exclusion Criteria 5

Surgical expertise-based randomization – > 2 years of experience as staff cardiac surgeon and – > 100 cases of one or both techniques – Trainees were not allowed to be primary operators Qualifications of Surgeons 6

1 st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization results presented ACC 2012 results at 1 year 2 nd Co-Primary Outcome Composite of above outcomes plus repeat coronary revascularization over 5 yrs of follow-up (expected 2016) Primary Outcomes 7

Secondary Efficacy Outcomes - Components of 1st co-Primary Outcome - Revascularization Other Outcomes - Recurrent angina, and CV mortality - Quality of life, neurocognitive function Other Outcomes – 1 Year 8

1 st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization 80% power to detect a 28% risk reduction 2 nd Co-Primary Outcome Composite of above outcomes plus repeat coronary re-revascularization over 5 yrs of follow-up (expected 2016) 90% power to detect a 20% risk reduction Statistical Power 9

OFF-PUMP (n = 2375) ON-PUMP (n = 2377) Mean Age (years) Males (%) Prior MI Previous Stroke Peripheral Arterial Disease Congestive Heart Failure Urgent Surgery Euroscore 0 – 2 3 – 5 > Baseline Characteristics 10

OFF-PUMP (n = 2375) % ON-PUMP (n = 2377) % Left Main Triple Vessel Double Vessel Single Vessel Baseline Disease – Pre-op Angiogram 11

Operation Details Randomized (ITT Analyses) Off PumpOn Pump CABG ≤ 30 days2148 (90.4%)2183(91.8%) Cross-overs184 (7.8%)150 (6.4%) Off Pump % On Pump % RR95% CIp value Incomplete revascularization Operating room (median hrs)4.04.2<0.001 Initial ventilation (median hrs) <0.001

1 st Co-Primary Outcome (1 Year) 13 Off Pump % On Pump % Hazard Ratio 95% CI p value Primary Outcome Death, Stroke, MI, Renal Failure

1 st Co-Primary Outcome (1 Year) 14 Off Pump % On Pump % Hazard Ratio 95% CI p value Primary Outcome Death, Stroke, MI, Renal Failure Components Death Stroke Non Fatal MI New Renal Failure

Death/MI/Stroke/New Renal Failure at 1 Year 15 HR % CI p value 0.24

Other Outcomes at 1 year 16 Off Pump % On Pump % Hazard Ratio 95% CIp value Cardiovascular Mortality Angina PCI Re-do CABG PCI/Re-do CABG Primary Outcome per Protocol

Primary Outcome between 31 days and 1 Year 17 Off Pump % On Pump % Hazard Ratio 95% CI p value Primary Outcome Death/MI/Stroke/Renal Failure Components Death Stroke Non Fatal MI New Renal Failure —2.71

Other Outcomes between 31 days and 1 Year 18 Off Pump % On Pump % Hazard Ratio 95% CIp value Cardiovascular Mortality Angina PCI Re-do CABG< PCI/Re-do CABG

Quality of Life 19

Neurocognitive Function 20

21 Subgroups (1)

Subgroups (2) 22

At 1 Year there was no difference between Off pump CABG and On pump CABG: – Primary Outcome – Individual components of the Primary Outcome – Revascularization procedures – Quality of Life – Neurocognitive functions Conclusions 23

In experienced hands, both procedures are reasonable options based on mid-term results Implications 24

A. Lamy (Co-PI)P.J. DevereauxJ. Murkin D.P. TaggartD. PrabhakaranR.J. Novick A.R. AkarS.E. FremesE. Paolasso A. AvezumS. HuL. Piegas R. CartierF. LanasZ. Straka S. ChocronP.J. LopezS. Yusuf (co-PI) Steering Committees 25

Final Recruitment by Country 4752 patients from 79 sites in 19 countries 26 Argentina (257) Canada (830) Brazil (358) Netherlands (27) Sweden (56) United Kingdom (227) France (4) Italy (48) USA (68) Czech Republic (298) Estonia (91) Turkey (132) Ukraine (11) Colombia (57) Australia (29) Uruguay (34) China (781) India (1307) Chile (137)

27